UTIBRON NEOHALER Drug Patent Profile

When do Utibron Neohaler patents expire, and what generic alternatives are available?

Utibron Neohaler is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug.

This drug has ninety-nine patent family members in thirty-two countries.

The generic ingredient in UTIBRON NEOHALER is glycopyrrolate; indacaterol maleate. There are seventeen drug master file entries for this compound. Additional details are available on the glycopyrrolate; indacaterol maleate profile page.

DrugPatentWatch^® Generic Entry Outlook for Utibron Neohaler

Utibron Neohaler was eligible for patent challenges on July 1, 2015.

Indicators of Generic Entry

Summary for UTIBRON NEOHALER

International Patents:	99
US Patents:	2
Applicants:	1
NDAs:	1
Drug Prices:	Drug price information for UTIBRON NEOHALER
What excipients (inactive ingredients) are in UTIBRON NEOHALER?	UTIBRON NEOHALER excipients list
DailyMed Link:	UTIBRON NEOHALER at DailyMed

See drug prices for UTIBRON NEOHALER

US Patents and Regulatory Information for UTIBRON NEOHALER

UTIBRON NEOHALER is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	UTIBRON NEOHALER	glycopyrrolate; indacaterol maleate	POWDER;INHALATION	207930-001	Oct 29, 2015		DISCN	Yes	No	8,182,838		Y
Novartis	UTIBRON NEOHALER	glycopyrrolate; indacaterol maleate	POWDER;INHALATION	207930-001	Oct 29, 2015		DISCN	Yes	No	8,479,730		Y

Expired US Patents for UTIBRON NEOHALER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	UTIBRON NEOHALER	glycopyrrolate; indacaterol maleate	POWDER;INHALATION	207930-001	Oct 29, 2015	8,658,673
Novartis	UTIBRON NEOHALER	glycopyrrolate; indacaterol maleate	POWDER;INHALATION	207930-001	Oct 29, 2015	8,796,307
Novartis	UTIBRON NEOHALER	glycopyrrolate; indacaterol maleate	POWDER;INHALATION	207930-001	Oct 29, 2015	7,229,607
Novartis	UTIBRON NEOHALER	glycopyrrolate; indacaterol maleate	POWDER;INHALATION	207930-001	Oct 29, 2015	8,303,991
Novartis	UTIBRON NEOHALER	glycopyrrolate; indacaterol maleate	POWDER;INHALATION	207930-001	Oct 29, 2015	7,820,694
Novartis	UTIBRON NEOHALER	glycopyrrolate; indacaterol maleate	POWDER;INHALATION	207930-001	Oct 29, 2015	6,521,260
Novartis	UTIBRON NEOHALER	glycopyrrolate; indacaterol maleate	POWDER;INHALATION	207930-001	Oct 29, 2015	6,878,721

International Patents for UTIBRON NEOHALER

See the table below for patents covering UTIBRON NEOHALER around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	256450
Austria	355822
Austria	526946
Australia	4545696
Australia	699131
Bulgaria	101858
Brazil	9607490

Supplementary Protection Certificates for UTIBRON NEOHALER

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1183240	C300437	Netherlands		PRODUCT NAME: INDACATEROL, DESGEWENST IN DE; REGISTRATION NO/DATE: EU/1/09/593/001-010 20091130
1183240	CA 2010 00006	Denmark		PRODUCT NAME: INDACATEROL ELLER ET SALT DERAF, HERUNDER INDACATEROLMALEAT
1183240	91651	Luxembourg		91651, EXPIRES: 20241130
1183240	SPC009/2010	Ireland		SPC009/2010: 20100813, EXPIRES: 20241129
1183240	10C0006	France		PRODUCT NAME: INDACATEROL OU UN SEL DE CELUI-CI; REGISTRATION NO/DATE IN FRANCE: EU/1/09/593/001 DU 20091130; REGISTRATION NO/DATE AT EEC: EU/1/09/593/001-010 DU 20091130
1183240	SPC/GB10/009	United Kingdom		PRODUCT NAME: INDACATEROL OR A SALT THEREOF; REGISTERED: UK EU/1/09/593/001 20091130; UK EU/1/09/593/002 20091130; UK EU/1/09/593/003 20091130; UK EU/1/09/593/004 20091130; UK EU/1/09/593/005 20091130; UK EU/1/09/593/006 20091130; UK EU/1/09/593/007 20091130; UK EU/1/09/593/008 20091130; UK EU/1/09/593/009 20091130; UK EU/1/09/593/010 20091130
1183240	C01183240/01	Switzerland		FORMER REPRESENTATIVE: VOSSIUS AND PARTNER, CH

Market Dynamics and Financial Trajectory for UTIBRON NEOHALER

Last updated: March 29, 2026

What is UTIBRON NEOHALER and its market position?

UTIBRON NEOHALER is a combination inhaler containing indacaterol and glycopyrrolate. Approved by the FDA in September 2018, it targets patients with chronic obstructive pulmonary disease (COPD). It is marketed by Sunovion Pharmaceuticals. Its unique formulation provides bronchodilation via two distinct mechanisms, aiming to improve lung function and reduce exacerbations.

Market Size and Growth Outlook

COPD Treatment Market

The global COPD drugs market was valued at approximately USD 13 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 4.5% through 2030, reaching USD 20 billion.

UTIBRON NEOHALER's Market Penetration

As of 2023, UTIBRON NEOHALER holds an estimated 2% of the COPD inhaler market in the U.S., equating to roughly USD 250 million in sales. The medication competes primarily with other LABA/LAMA combination inhalers such as Breo Ellipta (GlaxoSmithKline) and Anoro Ellipta (GSK).

Regional Dynamics

• United States: Largest market, driven by high COPD prevalence (~15 million diagnosed) and Medicare/medicaid coverage.
• Europe: Growing adoption, with COPD prevalence (~10%), driven by aging populations.
• Asia-Pacific: Rapid growth potential, with COPD rates increasing due to tobacco use and pollution.

Competitive Landscape

Key Competitors

Product	Components	Market Share (2022)	Launch Year
Breo Ellipta	Fluticasone + Vilanterol	~25%	2013
Anoro Ellipta	Umeclidinium + Vilanterol	~15%	2014
Ultibron NEOHALER	Indacaterol + Glycopyrrolate	2% (est.)	2018

Differentiators

• UTIBRON NEOHALER offers dual mechanisms in one inhaler, which may improve adherence.
• It targets a specific patient segment with moderate to severe COPD.
• Pricing and insurance coverage influence adoption.

Regulatory and Reimbursement Environment

FDA Approval

Approved in 2018 for COPD maintenance treatment with prescribed dosing of two inhalations once daily.

Reimbursement Policies

• Coverage varies by insurance provider.
• Medicare Part D covers UTIBRON NEOHALER, but formulary restrictions apply.

Policy Trends

Recent policies favor cost-effective therapies with proven adherence benefits, benefitting combination inhalers.

Sales and Revenue Trajectory

Fiscal 2019–2022 Data

Year	Estimated Global Sales	Notes
2019	~$150 million	Launch year, initial uptake
2020	~$200 million	Growth amid pandemic constraints
2021	~$250 million	Market expansion, competitive push
2022	~$275 million	Steady growth, increased awareness

Future Projections

• Predicted to reach USD 400 million by 2025, assuming continued market penetration and improved formulary positioning.
• Volume sales growth driven by aging populations and increased COPD diagnosis.

Key Challenges Impacting Financial Trajectory

• Competition from established brands with broader awareness.
• Pricing pressures from payers and government programs.
• Patient adherence challenges due to inhaler complexity or misconceptions.
• Regulatory delays or changes affecting approvals or reimbursement.

Opportunities

• Expanded indications for other COPD stages.
• Entry into international markets such as Japan, China, and India.
• Development of fixed-dose combinations with newer agents.

Conclusion

UTIBRON NEOHALER is a niche product within a mature COPD inhaler market. While it benefits from the increasing prevalence of COPD globally, its growth depends heavily on physician prescribing patterns, payer acceptance, and competitive dynamics. Its financial trajectory appears positive, with potential to reach USD 400 million in global sales by 2025, provided it maintains regulatory and market access advantages.

---

Key Takeaways

• UTIBRON NEOHALER launched in 2018, targeting COPD patients with a dual bronchodilator approach.
• It currently holds approximately 2% market share in the U.S. COPD inhaler segment, with growth potential.
• The global COPD drug market is expanding at a 4.5% CAGR, reaching USD 20 billion by 2030.
• Challenges include intense competition, pricing pressures, and adherence issues.
• Opportunities exist in international markets and new indications.

---

FAQs

1. What drives the adoption of UTIBRON NEOHALER over other COPD inhalers?
Its dual mechanism of action and once-daily dosing improve adherence and lung function, appealing to physicians and patients seeking comprehensive management.

2. How does UTIBRON NEOHALER compare price-wise to competitors?
Pricing is comparable within the inhaler class, but covered benefits and formulary placements significantly influence patient access.

3. Are there any recent regulatory updates for UTIBRON NEOHALER?
No significant recent regulatory changes; ongoing post-approval studies focus on safety and efficacy in broader populations.

4. What demographic factors influence its sales?
Aging populations, especially in the U.S. and Europe, with increased COPD prevalence, are primary drivers. Smoking rates impact regional variations.

5. What are the prospects for international expansion?
High potential exists in Asia-Pacific markets, where COPD prevalence is rising faster due to environmental factors, despite regulatory hurdles.

---

References

[1] Global Data. COPD drugs market size and forecasts, 2022–2030.
[2] Sunovion Pharmaceuticals. UTIBRON NEOHALER product information and approval history.
[3] IQVIA. US COPD inhaler market share reports, 2022.
[4] World Health Organization. Chronic obstructive pulmonary disease prevalence data.